

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 September 2021 (30.09.2021)



(10) International Publication Number
WO 2021/195467 A2

- (51) **International Patent Classification:**
A61K 31/713 (2006.01) *C12N 15/113* (2010.01)
- (21) **International Application Number:**
PCT/US2021/024299
- (22) **International Filing Date:**
26 March 2021 (26.03.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/000,137 26 March 2020 (26.03.2020) US
- (71) **Applicant: ARROWHEAD PHARMACEUTICALS, INC.** [US/US]; 177 E. Colorado Boulevard, Suite 700, Pasadena, CA 91105 (US).
- (72) **Inventors: NICHOLAS, Anthony;** c/o Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, Madison, WI 53719

(US). **PEI, Tao;** c/o Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, Madison, WI 53719 (US). **XU, Zhao;** c/o Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, Madison, WI 53719 (US). **SCHIENEBECK, Casi;** c/o Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, Madison, WI 53719 (US). **DING, Zhi-Ming;** c/o Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, Madison, WI 53719 (US).

(74) **Agent: GROTH, Felicity E.;** Baker & Hostetler, LLP, 2929 Arch Street, Cira Centre, 12th Floor, Philadelphia, PA 19104-2891 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,

(54) **Title:** RNAi AGENTS FOR INHIBITING EXPRESSION OF PNPLA3, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE




FIGURE 1

(57) **Abstract:** The present disclosure relates to RNAi agents, *e.g.*, double stranded RNAi agents, able to inhibit patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene expression. Also disclosed are pharmaceutical compositions that include PNPLA3 RNAi agents and methods of use thereof. The PNPLA3 RNAi agents disclosed herein may be conjugated to targeting ligands to facilitate the delivery to cells, including to hepatocytes. Delivery of the PNPLA3 RNAi agents *in vivo* provides for inhibition of PNPLA3 gene expression. The RNAi agents can be used in methods of treatment of PNPLA3 -related diseases and disorders, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hepatic fibrosis, and alcoholic or non-alcoholic liver diseases, including cirrhosis.

[Continued on next page]

WO 2021/195467 A2

NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*